论文部分内容阅读
Objective: The aim of this study was to observe and compare the antiemetic effectiveness and adverse events of magnetotherapy plus 5-hydroxytryptamine (5-HT3) receptor inhibitor granisetron hydrochloride vs granisetron hydrochloride alone in patients with chemotherapy. Methods: Sixty-four patients were randomized to receive either granisetron hydrochloride alone (control group: granisetron hydrochloride 3 mg intervenous infusion before chemotherapy, from the 1st day of chemotherapy course until the day after chemotherapy course completed) or magnetotherapy plus granisetron hydrochloride (treatment group: the same granisetron hydrochloride regimen plus rotatory magnetotherapy of 1 every day after chemotherapy for 5 begin with chemotherapy). Baseline characteristics were similar in both groups. The patients' emesia was evaluated according to WHO's criteria. The density of 5-HT3 was detected by enzyme-linked immunosorbent assay (ELISA). Results:In the treatment of acute vomiting, there was no significant difference between two groups (P ＞ 0.05), but in the treatment of tardive vomiting, the effectiveness in treatment group was better than that in control group (P ＜ 0.05). The density of 5-HT3 in treatment group and control group were (225.32 ± 57.29) ng/mL vs (213.00 ±53.29) ng/mL before chemotherapy and (273.88± 75.42) ng/mL vs (313.17 ± 76.36) ng/mL after chemotherapy (P ＜ 0.01); the rate of adverse events was 36.36% and 48.39%respectively in treatment group and control group (P ＞ 0.05). Conclusion: Magnetotherapy plus granisetron hydrochloride provide better effectiveness than granisetron hydrochloride alone, and both therapies have synergistic effect. The adverse events didn't raised in treatment group.